RESCRIPTOR

Compare RESCRIPTOR  to:
Compare
Compare

Generic Name for RESCRIPTOR

Delavirdine mesylate 100mg, 200mg; tabs.

Legal Classification:

Rx

Pharmacological Class for RESCRIPTOR

Non-nucleoside reverse transcriptase inhibitor.

Manufacturer of RESCRIPTOR

Pfizer Labs

Indications for RESCRIPTOR

HIV-1 infection.

Adult dose for RESCRIPTOR

Swallow whole or may disperse 100mg tabs in 3oz water and drink. ≥16yrs: 400mg 3 times daily.

Children's dosing for RESCRIPTOR

<16yrs: not recommended.

Contraindications for RESCRIPTOR

CYP3A substrates that may cause serious events if blood levels are elevated (eg, cisapride, pimozide, alprazolam, midazolam, triazolam, ergots).

Warnings/Precautions for RESCRIPTOR

Discontinue if serious rash (or rash with other symptoms) occurs. Hepatic dysfunction. Achlorhydria (take with an acidic beverage). Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for RESCRIPTOR

See Contraindications. Concomitant lovastatin or simvastatin: not recommended. May increase levels of antiarrhythmics (eg, quinidine), calcium channel blockers (eg, nifedipine), clarithromycin, rifabutin, indinavir, saquinavir (monitor ALT/AST), amprenavir, amphetamines, trazodone, warfarin, sildenafil, atorvastatin, fluvastatin, immunosuppressants, methadone, fluticasone (long-term use); serious or life-threatening adverse reactions may occur with some of these drugs (avoid or adjust dose). Delavirdine levels may be decreased by phenytoin, phenobarbital, carbamazepine, rifabutin, rifampin, chronic H2 antagonists or PPIs, dexamethasone, St. John's wort: not recommended; didanosine and vice versa (separate dosing by at least 1 hour). Delavirdine levels increased by fluoxetine, ketoconazole. Absorption reduced by antacids (separate dosing by at least 1 hour). Reduce indinavir dose (consider indinavir 600mg three times daily).

Adverse Reactions for RESCRIPTOR

Rash, GI upset, increased ALT/AST; immune reconstitution syndrome, fat redistribution.

How is RESCRIPTOR supplied?

Tabs 100mg—360
200mg—180

Related Disease:

HIV~antivirals

Related Resources

Abbott RealTime HBV test approved

September 02, 2010

Abbott announced that the FDA has approved its RealTime HBV assay for measuring the amount of hepatitis B virus (HBV) in human plasma or serum from individuals chronically infected with HBV.

Longer use of Valcyte for renal transplant patients approved

August 11, 2010

The FDA has approved a longer duration of therapy with Valcyte (valganciclovir, from Genentech) in adult renal transplant patients at high risk for cytomegalovirus (CMV) disease.

Phase 3 study of boceprevir for the treatment of HCV

August 05, 2010

Merck announced the completion and results of its two Phase 3 studies for boceprevir for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection.

Afluria labeling updated to include fever and febrile seizure risk

August 02, 2010

The Prescribing Information for Afluria (trivalent, inactivated, "split virus" influenza vaccine [Types A and B], from CSL Biotherapies) has been updated to inform healthcare professionals of an increased incidence of fever and febrile seizure among young children in Australia, mainly those <5years of age.

Fluzone available for 2010-2011 influenza season

July 30, 2010

Sanofi Pasteur announced that it has begun shipping the 2010-2011 formulation of Fluzone (trivalent inactivated "split virus" influenza vaccine [Types A and B]).

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions